본문 바로가기 주메뉴 바로가기
  • HOME
  • Public Relations
  • GC Cell News

GC Cell News

Green Cross Cell signed a contract of joint research and sales with AroCell
2017-12-22

Green Cross Cell has signed a contract with AroCell, a cancer cell biomarker research company, for joint research and exclusive sales of ‘TK 210 ELISA’ in Korea.

AroCell is a cancer cell biomarker research company, which has developed ‘TK 210 ELISA’, an immunoassay kit capable of detecting thymidine kinase Ι in human serum. It is currently listed on Nasdaq First North.

Through this contract, Green Cross Cell will have sales exclusivity of ‘TK 210 ELISA ', a cancer cell biomarker, in Korea and will increase cooperation in developing next-generation immune carcinoma drugs. 'TK 210 ELISA' is a fast and easy way to analyze Thymidine Kinase Ι, which is present in patient's blood and is already used as a cancer cell growth biomarker overseas.

Green Cross Cell hopes to achieve visible results in developing next-generation cell therapy products via AroCell's biomarker technology.

Next
GC Cell Entered into an Agreement of Cooperation to go to Russia
Previous
Green Cross Cell is certified as a ‘SME of Human Resources Development’